Biohaven Pharmaceutical Holding Company Ltd. BHVN 深 沪
等待开盘 11-05 09:30:00 美东时间
13.95
-0.900
-6.06%
华盛通- 最 高14.815
- 今 开14.61
- 成交量 273.59万股
- 最 低 13.65
- 昨 收 14.85
- 总市值 14.23亿
- 52周最高 47.75
- 市盈率 静 --
- 换手率 2.68%
- 52周最低 12.79
- 委 比 46.16%
- 总股本 1.02亿
- 历史最高 152.56
- 量 比 1.06
- 振 幅 7.85%
- 历史最低 7.10
- 每 手 1
- 风险率 12.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
11-03 21:14
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
09-30 01:35
花旗予Biohaven(BHVN.US)“买入”评级 看好其核心药物曲鲁唑获FDA批准潜力
Biohaven核心驱动因素在于主要资产曲鲁唑(troriluzole)有望潜在获得FDA批准，花旗银行给予该股买入评级并设定每股28美元目标价。
09-18 14:22
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
UBS Maintains Buy on Biohaven, Lowers Price Target to $26
UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $27 to $26.
09-16 20:43
Gilead, Moderna to see upside if RFK Jr. leaves HHS: RBC
As HHS Secretary Robert F. Kennedy Jr. continues to fend off criticism of his leadership and decisions at the agency, if he were to leave the post, Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA)...
09-11 03:54
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Raymond James Initiates Coverage On Biohaven with Strong Buy Rating, Announces Price Target of $75
Raymond James analyst Chris Raymond initiates coverage on Biohaven (NYSE:BHVN) with a Strong Buy rating and announces Price Target of $75.
09-04 00:44
BHVN Lawsuit Alert! Class Action Lawsuit Against Biohaven Ltd.
Aclass actionlawsuit was filed againstBiohaven Ltd. ($BHVN) b...
08-28 17:55
